Nxera Pharma Co., Ltd. (OTCMKTS:SOLTF – Get Free Report) shares fell 5.7% on Friday . The stock traded as low as $9.43 and last traded at $9.43. 50 shares were traded during trading, a decline of 97% from the average session volume of 1,941 shares. The stock had previously closed at $10.00.
Nxera Pharma Stock Performance
The firm has a 50-day simple moving average of $9.51 and a two-hundred day simple moving average of $9.88.
About Nxera Pharma
Nxera Pharma Co, Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and PIVLAZ for the treatment of cerebral vasospasm indications.
Read More
- Five stocks we like better than Nxera Pharma
- How to Invest in Insurance Companies: A Guide
- McDonald’s Stock: Balancing Value and Innovation
- How to Start Investing in Real Estate
- MarketBeat Week in Review – 6/17 – 6/21
- What is a Low P/E Ratio and What Does it Tell Investors?
- Sarepta Therapeutics Stock Soars on FDA Approval
Receive News & Ratings for Nxera Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nxera Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
